Anti-C1q is a novel biomarker with demonstrated utility in assessing renal activity and SLE disease activity. Studies demonstrate anti-C1q may be helpful in identifying the 45% to 61% of SLE patients with renal involvement.

Antibodies to Beta 2 Glycoprotein 1 (β2 GP1) show higher specificity than anti-cardiolipin assays. In 3-10% of APS patients, β2 GP1 antibody may be the only positive test. Antibodies to Beta 2 Glycoprotein 1 (β2 GP1) IgA are less prevalent than IgG or IgM but can occur in isolation. Positive results should be confirmed after 12 weeks.

*Note these markers are included and reported with AVISE CTD and will not be repeated when ordered with AVISE CTD